New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
10:01 EDTMLNX, FIO, ABBV, PFE, SYRG, VRTX, VCLK, RBCN, TRLA, OPTR, FLY, DLA, GOOGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Delta Apparel (DLA) initiated with a Buy at Roth Capital... Fly Leasing (FLY) initiated with a Buy at Deutsche Bank... Google (GOOG) initiated with a Neutral at Sterne Agee... Optimer (OPTR) initiated with an Outperform at RW Baird... Trulia (TRLA) initiated with a Neutral at Goldman... ValueClick (VCLK) initiated with a Buy at Goldman... Vertex (VRTX) initiated with an Outperform at RW Baird... Rubicon (RBCN) coverage resumed with an Underweight at Piper Jaffray... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Pfizer (PFE) reinstated with a Neutral at Credit Suisse... AbbVie (ABBV) initiated with a Neutral at Credit Suisse... Fusion-io (FIO) initiated with a Neutral at Janney Capital... Mellanox (MLNX) initiated with a Buy at Janney Capital.
News For GOOG;DLA;FLY;OPTR;TRLA;RBCN;VCLK;VRTX;SYRG;PFE;ABBV;FIO;MLNX From The Last 14 Days
Check below for free stories on GOOG;DLA;FLY;OPTR;TRLA;RBCN;VCLK;VRTX;SYRG;PFE;ABBV;FIO;MLNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 22, 2014
15:15 EDTGOOGGoogle wins victory in German publisher complaint, Re/code says
Subscribe for More Information
14:19 EDTPFEViiV Healthcare receives FDA approval for HIV-1 treatment Triumeq
Subscribe for More Information
13:53 EDTGOOGGoogle acquires Gecko Design
Subscribe for More Information
August 21, 2014
15:16 EDTABBVDEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
13:32 EDTPFEBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
09:54 EDTPFEPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
08:02 EDTPFEPfizer initiates U.S. EAP for palbociclib.
Pfizer announced that the company has initiated a multi-center, open-label expanded access program in the U.S. for palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer for whom letrozole is considered appropriate therapy.
07:57 EDTABBVGilead HCV risks overblown, says Bernstein
Bernstein believes that investors are concerned about upcoming competition to Gilead's (GILD) HCV drug from AbbVie's (ABBV) HCV treatment. But Bernstein says that insurers can only prevent 16% of the U.S. population from receiving Gilead's drug, and the firm does not expect the HCV market share dynamics to change in the near-term. It keeps an Outperform rating on Gilead.
07:55 EDTPFEActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTPFEPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
06:21 EDTGOOGGM product chief thinks Google might become 'threat,' Bloomberg says
Subscribe for More Information
06:05 EDTGOOGGoogle unit leads $100M infusion in Thumbtack, WSJ reports
Google's Google Capital unit is leading a $100M funding round in Thumbtack, a services marketplace, the Wall Street Journal reports. The investment, which also includes Tiger Global Management and Sequoia Capital, values Thumbtack at over $800M. Reference Link
August 20, 2014
13:46 EDTGOOGVerizon looking to build app store, The Information says
Verizon (VZ) is looking to partner with other companies to build an app store, according to The Information. Verizon's app store would compete with Google (GOOG) and Apple (AAPL), which already sell smartphone software, The Information noted. Reference Link
09:24 EDTGOOGVringo intends to seek en banc review of decision in I/P Engine case
Vringo (VRNG) announced that its wholly-owned subsidiary I/P Engine, Inc. intends to file a petition with the United States Court of Appeals for the Federal Circuit seeking en banc review of the split appellate decision in its case against AOL (AOL), Google (GOOG) et al. that issued on August 15 and reversed the judgment of the United States District Court for the Eastern District of Virginia. Under the Federal Circuit's rules, I/P Engine's petition for en banc review is due on September 15. I/P Engine has filed an unopposed motion seeking a 30-day extension, which would make its petition due October 15. Upon receiving the requested extension, I/P Engine may file the petition on or anytime prior to October 15.
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
07:01 EDTGOOGGarmin introduces first Android-based fleet navigators
Subscribe for More Information
06:36 EDTGOOGIliad speaks to Google, Microsoft regarding T-Mobile offer, NY Post says
After Iliad's (ILIAF) surprise bid for T-Mobile (TMUS) was rejected, the firm is now in contact with , personnel at Google (GOOG) and Microsoft (MSFT) about working together to come up with a larger offer for the company, according to the New York Post, citing a "well-placed" source. Reference Link
August 19, 2014
06:50 EDTGOOGImages show impending Google music subscription service, Android Police says
Subscribe for More Information
06:13 EDTGOOGContinental AG hires Google's Seval Oz to lead new division, WSJ reports
Subscribe for More Information
05:57 EDTGOOGGoogle to offer accounts to children under 13, WSJ reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use